{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:57:31Z","timestamp":1759481851529},"reference-count":120,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14155","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T11:57:08Z","timestamp":1700135828000},"source":"Crossref","is-referenced-by-count":4,"title":["Current status and perspectives of genetic testing in gastrointestinal cancer (Review)"],"prefix":"10.3892","volume":"27","author":[{"given":"Tasuku","family":"Matsuoka","sequence":"first","affiliation":[{"name":"Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka 5458585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yashiro","sequence":"additional","affiliation":[{"name":"Institute of Medical Genetics, Osaka Metropolitan University, Osaka 5458585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"key20231221130741_b1-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key20231221130741_b2-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3892\/etm.2022.11112","article-title":"From chronic pruritus to neuroendocrine tumor: A case report","volume":"23","author":"Ceasovschih","year":"2022","journal-title":"Exp Ther Med"},{"key":"key20231221130741_b3-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000334677","article-title":"Recent advances in diagnosis and treatment for malignancies of the gastrointestinal tract","volume":"85","author":"Watanabe","year":"2012","journal-title":"Digestion"},{"key":"key20231221130741_b4-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4251\/wjgo.v12.i1.1","article-title":"Precision medicine for gastrointestinal cancer: Recent progress and future perspective","volume":"12","author":"Matsuoka","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"key20231221130741_b5-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cas.13837","article-title":"Next generation sequencing-based gene panel tests for the management of solid tumors","volume":"110","author":"Nagahashi","year":"2019","journal-title":"Cancer Sci"},{"key":"key20231221130741_b6-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/mutage\/geu031","article-title":"Next-generation sequencing technologies: Breaking the sound barrier of human genetics","volume":"29","author":"Bahassi el","year":"2014","journal-title":"Mutagenesis"},{"key":"key20231221130741_b7-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"key20231221130741_b8-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"key20231221130741_b9-ol-27-1-14155","first-page":"525","article-title":"Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors","volume":"7","author":"Cobain","year":"2021","journal-title":"JAMA Oncol"},{"key":"key20231221130741_b10-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the know your tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20231221130741_b11-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"key20231221130741_b12-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20231221130741_b13-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","article-title":"Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b14-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1158\/1078-0432.CCR-19-2004","article-title":"Response to anti-EGFR therapy in patients with BRAF non-V600-mutant metastatic colorectal cancer","volume":"25","author":"Yaeger","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20231221130741_b15-ol-27-1-14155","article-title":"Atypical, non-V600 BRAF mutations as a potential mechanism of resistance to EGFR inhibition in metastatic colorectal cancer","volume":"3","author":"Johnson","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"key20231221130741_b16-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"key":"key20231221130741_b17-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-15-0412","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20231221130741_b18-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2159-8290.CD-16-0795","article-title":"A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer","volume":"7","author":"van Geel","year":"2017","journal-title":"Cancer Discov"},{"key":"key20231221130741_b19-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b20-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"key20231221130741_b21-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"100795","DOI":"10.1016\/j.tranon.2020.100795","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"13","author":"Roviello","year":"2020","journal-title":"Transl Oncol"},{"key":"key20231221130741_b22-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","article-title":"Management of BRAF-mutant metastatic colorectal cancer: A review of treatment options and evidence-based guidelines","volume":"32","author":"Grothey","year":"2021","journal-title":"Ann Oncol"},{"key":"key20231221130741_b23-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"101974","DOI":"10.1016\/j.ctrv.2020.101974","article-title":"KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?","volume":"84","author":"Nagasaka","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20231221130741_b24-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11912-021-01022-0","article-title":"Targeting KRAS in colorectal cancer","volume":"23","author":"Wang","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"key20231221130741_b25-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2015.65.1067","article-title":"Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels","volume":"34","author":"Stadler","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b26-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-14-3051","article-title":"Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: A rationale for personalized immunotherapy","volume":"75","author":"Maby","year":"2015","journal-title":"Cancer Res"},{"key":"key20231221130741_b27-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","article-title":"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20231221130741_b28-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.4679","article-title":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","volume":"238","author":"Richman","year":"2016","journal-title":"J Pathol"},{"key":"key20231221130741_b29-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s12094-019-02213-9","article-title":"Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer","volume":"22","author":"Wang","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"key20231221130741_b30-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20231221130741_b31-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20231221130741_b32-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20231221130741_b33-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"key":"key20231221130741_b34-ol-27-1-14155","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"key20231221130741_b35-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejps.2016.08.019","article-title":"Molecularly imprinted microparticles in lipid-based formulations for sustained release of donepezil","volume":"93","author":"Ruela","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"key20231221130741_b36-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/path.4884","article-title":"Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4","volume":"242","author":"Hosoda","year":"2017","journal-title":"J Pathol"},{"key":"key20231221130741_b37-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"key20231221130741_b38-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat Commun"},{"key":"key20231221130741_b39-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b40-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"key20231221130741_b41-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b42-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: Past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"key20231221130741_b43-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20231221130741_b44-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"key20231221130741_b45-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20231221130741_b46-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b47-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"key20231221130741_b48-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1002\/ijc.32408","article-title":"[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification","volume":"145","author":"Takegawa","year":"2019","journal-title":"Int J Cancer"},{"key":"key20231221130741_b49-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"key20231221130741_b50-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20231221130741_b51-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"152878","DOI":"10.1016\/j.prp.2020.152878","article-title":"High-level FGFR2 amplification is associated with poor prognosis and lower response to chemotherapy in gastric cancers","volume":"216","author":"Hur","year":"2020","journal-title":"Pathol Res Pract"},{"key":"key20231221130741_b52-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1200\/JCO.19.01834","article-title":"Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma","volume":"38","author":"Catenacci","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b53-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2217\/fon-2019-0141","article-title":"Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design","volume":"15","author":"Catenacci","year":"2019","journal-title":"Future Oncol"},{"key":"key20231221130741_b54-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun"},{"key":"key20231221130741_b55-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"key20231221130741_b56-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s13059-014-0436-9","article-title":"Diverse modes of genomic alteration in hepatocellular carcinoma","volume":"15","author":"Jhunjhunwala","year":"2014","journal-title":"Genome Biol"},{"key":"key20231221130741_b57-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"wheeler@bcm.edu; Cancer Genome Atlas Research Network: Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Cancer Genome Atlas Research Network. Electronic address","year":"2017","journal-title":"Cell"},{"key":"key20231221130741_b58-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1038\/emm.2017.158","article-title":"Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway","volume":"50","author":"Xu","year":"2018","journal-title":"Exp Mol Med"},{"key":"key20231221130741_b59-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3","article-title":"p16 is a major inactivation target in hepatocellular carcinoma","volume":"89","author":"Jin","year":"2000","journal-title":"Cancer"},{"key":"key20231221130741_b60-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"key20231221130741_b61-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"key20231221130741_b62-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"key20231221130741_b63-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"key20231221130741_b64-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"key20231221130741_b65-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20231221130741_b66-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"key20231221130741_b67-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1634\/theoncologist.2017-0621","article-title":"Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer","volume":"23","author":"Nakamura","year":"2018","journal-title":"Oncologist"},{"key":"key20231221130741_b68-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"e000600","DOI":"10.1136\/esmoopen-2019-000600","article-title":"Development of circulating tumour DNA analysis for gastrointestinal cancers","volume":"5","author":"Nakamura","year":"2020","journal-title":"ESMO Open"},{"key":"key20231221130741_b69-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20231221130741_b70-ol-27-1-14155","first-page":"46","article-title":"The first liquid biopsy test approved","volume":"5","author":"Kwapisz","year":"2017","journal-title":"Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med"},{"key":"key20231221130741_b71-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of american pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b72-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"eaax7533","DOI":"10.1126\/scitranslmed.aax7533","article-title":"Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer","volume":"12","author":"Luo","year":"2020","journal-title":"Sci Transl Med"},{"key":"key20231221130741_b73-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mrfmmm.2015.05.002","article-title":"Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients","volume":"778","author":"Balgkouranidou","year":"2015","journal-title":"Mutat Res"},{"key":"key20231221130741_b74-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/annonc\/mdy083","article-title":"Genetic profiling using plasma-derived cell-free DNA in therapy-na\u00efve hepatocellular carcinoma patients: A pilot study","volume":"29","author":"Ng","year":"2018","journal-title":"Ann Oncol"},{"key":"key20231221130741_b75-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/hep.30244","article-title":"Hepatocellular carcinoma detection by plasma methylated DNA: Discovery, phase I pilot, and phase II clinical validation","volume":"69","author":"Kisiel","year":"2019","journal-title":"Hepatology"},{"key":"key20231221130741_b76-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1479-5876-9-75","article-title":"The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting","volume":"9","author":"Maleddu","year":"2011","journal-title":"J Transl Med"},{"key":"key20231221130741_b77-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.3390\/cancers13225698","article-title":"Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors","volume":"13","author":"Larrib\u00e8re","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20231221130741_b78-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: A retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20231221130741_b79-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci"},{"key":"key20231221130741_b80-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"key20231221130741_b81-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"key20231221130741_b82-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","article-title":"Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"key":"key20231221130741_b83-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.annonc.2019.10.007","article-title":"Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: Challenges and future perspectives","volume":"31","author":"Martinelli","year":"2020","journal-title":"Ann Oncol"},{"key":"key20231221130741_b84-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: A phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"key":"key20231221130741_b85-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"},{"key":"key20231221130741_b86-ol-27-1-14155","first-page":"220","article-title":"Multi gene panel testing for hereditary breast cancer-is it ready to be used?","volume":"92","author":"Catana","year":"2019","journal-title":"Med Pharm Rep"},{"key":"key20231221130741_b87-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/annonc\/mdz233","article-title":"clinicalguidelines@esmo.org: Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Stjepanovic","year":"2019","journal-title":"Ann Oncol"},{"key":"key20231221130741_b88-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20231221130741_b89-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/jmedgenet-2017-105188","article-title":"Consensus for genes to be included on cancer panel tests offered by UK genetics services: Guidelines of the UK Cancer Genetics Group","volume":"55","author":"Taylor","year":"2018","journal-title":"J Med Genet"},{"key":"key20231221130741_b90-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/path.5422","article-title":"Molecular pathology of Lynch syndrome","volume":"250","author":"Cerretelli","year":"2020","journal-title":"J Pathol"},{"key":"key20231221130741_b91-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/jnci\/djs351","article-title":"Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome","volume":"104","author":"Win","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"key20231221130741_b92-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ajg.2014.435","article-title":"ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes","volume":"110","author":"Syngal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"key20231221130741_b93-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b94-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.bpg.2016.10.013","article-title":"Surveillance for neoplasia in the pancreas","volume":"30","author":"Overbeek","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"key20231221130741_b95-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20231221130741_b96-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/gim.2017.85","article-title":"Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history","volume":"20","author":"Chaffee","year":"2018","journal-title":"Genet Med"},{"key":"key20231221130741_b97-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"key":"key20231221130741_b98-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrgastro.2012.111","article-title":"Familial pancreatic cancer-current knowledge","volume":"9","author":"Bartsch","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20231221130741_b99-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee: A practice guideline from the American college of medical genetics and genomics and the national society of genetic counselors: Referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"key":"key20231221130741_b100-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-051019-103216","article-title":"Hereditary diffuse gastric cancer: Approaches to screening, surveillance, and treatment","volume":"72","author":"Pilonis","year":"2021","journal-title":"Annu Rev Med"},{"key":"key20231221130741_b101-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10689-015-9778-z","article-title":"Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer","volume":"14","author":"Donner","year":"2015","journal-title":"Fam Cancer"},{"key":"key20231221130741_b102-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20231221130741_b103-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1038\/onc.2015.90","article-title":"Cancer whole-genome sequencing: Present and future","volume":"34","author":"Nakagawa","year":"2015","journal-title":"Oncogene"},{"key":"key20231221130741_b104-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"100487","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When should we order a next generation sequencing test in a patient with cancer?","volume":"25","author":"Colomer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"key20231221130741_b105-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","journal-title":"Nature"},{"key":"key20231221130741_b106-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12920-019-0500-0","article-title":"Sequencing and curation strategies for identifying candidate glioblastoma treatments","volume":"12","author":"Frank","year":"2019","journal-title":"BMC Med Genomics"},{"key":"key20231221130741_b107-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1097\/SLA.0000000000004213","article-title":"Whole-exome Sequencing reveals new potential susceptibility genes for Japanese familial pancreatic cancer","volume":"275","author":"Takai","year":"2022","journal-title":"Ann Surg"},{"key":"key20231221130741_b108-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/cge.14038","article-title":"Whole genome sequencing identifies rare germline variants enriched in cancer related genes in first degree relatives of familial pancreatic cancer patients","volume":"100","author":"Tan","year":"2021","journal-title":"Clin Genet"},{"key":"key20231221130741_b109-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41388-020-01537-z","article-title":"Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer","volume":"40","author":"Bala","year":"2021","journal-title":"Oncogene"},{"key":"key20231221130741_b110-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41467-021-23629-4","article-title":"Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features","volume":"12","author":"Mendelaar","year":"2021","journal-title":"Nat Commun"},{"key":"key20231221130741_b111-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1038\/s41467-018-07041-z","article-title":"Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer","volume":"9","author":"Ishaque","year":"2018","journal-title":"Nat Commun"},{"key":"key20231221130741_b112-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"215767","DOI":"10.1016\/j.canlet.2022.215767","article-title":"Clonality and timing of relapsing colorectal cancer metastasis revealed through whole-genome single-cell sequencing","volume":"543","author":"Alves","year":"2022","journal-title":"Cancer Lett"},{"key":"key20231221130741_b113-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.1038\/s41598-021-94064-0","article-title":"Exome sequencing identifies novel somatic variants in African American esophageal squamous cell carcinoma","volume":"11","author":"Erkizan","year":"2021","journal-title":"Sci Rep"},{"key":"key20231221130741_b114-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1038\/s41467-021-24109-5","article-title":"Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS","volume":"12","author":"Rose Brannon","year":"2021","journal-title":"Nat Commun"},{"key":"key20231221130741_b115-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"key":"key20231221130741_b116-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-0716-1099-2_2","article-title":"The illumina sequencing protocol and the novaseq 6000 system","volume":"2242","author":"Modi","year":"2021","journal-title":"Methods Mol Biol"},{"key":"key20231221130741_b117-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1177932219899051","DOI":"10.1177\/1177932219899051","article-title":"Multi-omics data integration, interpretation, and its application","volume":"14","author":"Subramanian","year":"2020","journal-title":"Bioinform Biol Insights"},{"key":"key20231221130741_b118-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"key":"key20231221130741_b119-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature13438","article-title":"Proteogenomic characterization of human colon and rectal cancer","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"key20231221130741_b120-ol-27-1-14155","doi-asserted-by":"publisher","first-page":"eaay4211","DOI":"10.1126\/sciadv.aay4211","article-title":"Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy","volume":"6","author":"Li","year":"2020","journal-title":"Sci Adv"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T11:22:27Z","timestamp":1703157747000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,16]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14155","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"21"}}